Regulus Therapeutics Inc. (RGLS) announced after the bell Monday that it has received verbal notification from the FDA that RG-101 has been placed on clinical hold. The treatment for chronic hepatitis C virus infection was put on hold after Regulus reported a second serious adverse event of jaundice. The stock is now down 2.86 on 90K shares.
Regulus Therapeutics declined until mid-morning Monday and finished with a loss of 0.28 at $5.01 on above average volume. The stock closed testing the lower end of a 2-month trading range.
For comments and feedback contact: editorial@rttnews.com
Business News